Cutera, Inc. (NASDAQ:CUTR) has earned a consensus rating of “Buy” from the seven research firms that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $39.50.

Several analysts recently commented on the stock. Maxim Group reaffirmed a “hold” rating on shares of Cutera in a report on Wednesday, November 8th. BidaskClub raised shares of Cutera from a “hold” rating to a “buy” rating in a report on Saturday, August 12th. TheStreet raised shares of Cutera from a “c” rating to a “b” rating in a report on Friday, August 18th. Roth Capital boosted their price objective on shares of Cutera from $32.00 to $39.00 and gave the company a “buy” rating in a report on Tuesday, August 8th. Finally, Gabelli reissued a “buy” rating on shares of Cutera in a report on Wednesday, August 9th.

COPYRIGHT VIOLATION NOTICE: “Brokerages Set Cutera, Inc. (CUTR) Price Target at $39.50” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/11/17/brokerages-set-cutera-inc-cutr-price-target-at-39-50-2.html.

Shares of Cutera (NASDAQ CUTR) traded up $0.05 during mid-day trading on Tuesday, hitting $42.50. 340,134 shares of the company traded hands, compared to its average volume of 141,468. The company has a market cap of $594.51, a P/E ratio of 56.03, a price-to-earnings-growth ratio of 1.89 and a beta of 0.49. Cutera has a 1-year low of $14.45 and a 1-year high of $47.15.

Cutera (NASDAQ:CUTR) last announced its earnings results on Tuesday, November 7th. The medical device company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.08 by $0.34. The business had revenue of $38.17 million during the quarter, compared to the consensus estimate of $34.82 million. Cutera had a net margin of 7.99% and a return on equity of 18.73%. Cutera’s revenue was up 26.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.12 EPS. equities research analysts forecast that Cutera will post 0.55 EPS for the current year.

Cutera announced that its board has initiated a share buyback plan on Monday, August 7th that allows the company to repurchase $25.00 million in shares. This repurchase authorization allows the medical device company to buy up to 6.8% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s leadership believes its stock is undervalued.

In other news, EVP Larry Laber sold 1,250 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $44.30, for a total value of $55,375.00. Following the completion of the transaction, the executive vice president now directly owns 70,463 shares in the company, valued at approximately $3,121,510.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Ronald J. Santilli sold 5,775 shares of the business’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $40.43, for a total transaction of $233,483.25. Following the completion of the transaction, the chief financial officer now owns 50,012 shares of the company’s stock, valued at $2,021,985.16. The disclosure for this sale can be found here. Insiders sold a total of 27,672 shares of company stock valued at $1,080,901 in the last three months. Insiders own 11.60% of the company’s stock.

Large investors have recently modified their holdings of the company. Kennedy Capital Management Inc. acquired a new position in Cutera during the 2nd quarter worth approximately $9,426,000. Stonepine Capital Management LLC acquired a new position in Cutera during the 2nd quarter worth approximately $4,533,000. Summit Creek Advisors LLC acquired a new position in Cutera during the 2nd quarter worth approximately $3,380,000. Ameriprise Financial Inc. acquired a new position in Cutera during the 2nd quarter worth approximately $3,175,000. Finally, EAM Investors LLC increased its position in Cutera by 148.7% during the 2nd quarter. EAM Investors LLC now owns 197,485 shares of the medical device company’s stock worth $5,115,000 after purchasing an additional 118,073 shares in the last quarter. Institutional investors own 89.72% of the company’s stock.

Cutera Company Profile

Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.

Receive News & Stock Ratings for Cutera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera Inc. and related stocks with our FREE daily email newsletter.